Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 20/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126312 | 1.00 | FGFR3 (0.72) | FGFR3 | |
| SCHEMBL1126457 | 0.94 | FGFR3 (0.74) | FGFR3 | |
| SCHEMBL1126325 | 0.93 | FGFR3 (0.65) | FGFR3 | |
| SCHEMBL1126543 | 0.92 | FGFR3 (0.62) | FGFR3 | |
| SCHEMBL1126319 | 0.90 | FGFR3 (0.73) | FGFR3 | |
| SCHEMBL1126507 | 0.90 | FGFR3 (0.72) | FGFR3 | |
| SCHEMBL1126376 | 0.89 | FGFR3 (0.61) | FGFR3 | |
| SCHEMBL17023165 | 0.88 | FGFR3 (0.55) | FGFR3 | |
| SCHEMBL1126289 | 0.87 | FGFR3 (0.59) | FGFR3 | |
| SCHEMBL12678423 | 0.86 | FGFR3 (0.58) | FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382365-A1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | NOVARTIS AG (CH) | 2025-12-18 | — | — | US | disclosed |
| US-20250195478-A1 | DUAL INHIBITORS OF VISTA AND PD-1 PATHWAYS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-06-19 | — | — | US | disclosed |
| US-20250144082-A1 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-05-08 | — | — | US | disclosed |
| US-12252535-B2 | Antibody molecules to LAG-3 and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| US-12226402-B2 | Dual inhibitors of TIM-3 and PD-1 pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2025-02-18 | — | — | US | disclosed |
| CN-119192383-A | ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies | 诺华股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-112218656-B | ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies | 诺华股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240343808-A1 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | BioAlta, LLC | 2024-10-17 | — | — | US | disclosed |
| US-20240336701-A1 | ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2024-10-10 | — | — | US | disclosed |
| EP-4424322-A2 | ANTIBODY MOLECULES TO PD-1 AND USES THEREOF | Novartis AG (CH) | 2024-09-04 | — | — | EP | disclosed |
| CN-111263767-B | Cyclic dinucleotides as stimulators of interferon gene modulators | 北京轩义医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20230081191-A1 | CONJOINT THERAPIES FOR IMMUNOMODULATION | AURIGENE ONCOLOGY LIMITED (IN) | 2023-03-16 | — | — | US | disclosed |
| US-20230062570-A1 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-03-02 | — | — | US | disclosed |
| CN-109843903-B | Cyclic dinucleotide compounds | 勃林格殷格翰国际有限公司 | 2023-01-24 | — | — | CN | disclosed |
| EP-4114417-A2 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2023-01-11 | — | — | EP | disclosed |
| CN-115427051-A | Therapeutic agents and conjugates thereof | 北京轩义医药科技有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-11497734-B2 | Dual inhibitors of TIM-3 and PD-1 pathways | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-11-15 | — | — | US | disclosed |
| US-11497735-B2 | Conjoint therapies for immunomodulation | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-11-15 | — | — | US | disclosed |
| EP-4031578-A1 | ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| CN-114502590-A | ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies | 诺华股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144082-A1 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | PDCD1, PDCD1LG2, CD274 | FGFR3 619/4885 |
| US-20250195478-A1 | DUAL INHIBITORS OF VISTA AND PD-1 PATHWAYS | PDCD1, PDCD1LG2, CD274 | FGFR3 742/4885 |
| US-20230081191-A1 | CONJOINT THERAPIES FOR IMMUNOMODULATION | CD274, PDCD1LG2, PDCD1 | FGFR3 349/4885 |
| US-11497734-B2 | Dual inhibitors of TIM-3 and PD-1 pathways | PDCD1, PDCD1LG2, CD274 | FGFR3 619/4885 |
| US-12252535-B2 | Antibody molecules to LAG-3 and uses thereof | CD274, PDCD1LG2, HAVCR2 | FGFR3 324/4885 |
| US-12226402-B2 | Dual inhibitors of TIM-3 and PD-1 pathways | PDCD1, PDCD1LG2, CD274 | FGFR3 619/4885 |
| US-20230062570-A1 | DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYS | PDCD1, PDCD1LG2, CD274 | FGFR3 619/4885 |
| US-20240336701-A1 | ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES | ENTPD2, ENTPD1, ENTPD3 | FGFR3 224/4885 |
| US-20250382365-A1 | ANTIBODY MOLECULES TO LAG-3 AND USES THEREOF | CD47, CD2, CD58 | FGFR3 230/4885 |
| US-11497735-B2 | Conjoint therapies for immunomodulation | CD274, PDCD1LG2, PDCD1 | FGFR3 349/4885 |
| US-20240343808-A1 | ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES | CD274, PDCD1LG2, PDCD1 | FGFR3 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.